Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KCNK15 and WISP2 antisense RNA 1 (KCNK15-AS1)
- Target
- KCNK15-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
KCNK15 and WISP2 antisense RNA 1 (KCNK15-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the KCNK15 and WISP2 genes[3][8]. It does not encode a protein but regulates the expression of neighboring and related genes via RNA-mediated mechanisms[4]. KCNK15-AS1 has been implicated in multiple cancers, playing divergent roles: it is generally **downregulated in pancreatic cancer, where its overexpression inhibits cell proliferation, migration, and EMT, and promotes apoptosis**[1][6]; in contrast, it is **overexpressed in lung adenocarcinoma, associated with poorer prognosis and appears to function as an oncogene**, enhancing proliferation by modulating the miR-202/miR-370/EGFR axis[2]. Its expression is subject to epigenetic regulation, especially m6A methylation status influenced by ALKBH5[1][6]. KCNK15-AS1 is emerging as a prognostic biomarker in both pancreatic and lung cancers, but it is not currently established as a therapeutic direct drug target, receptor, enzyme, or transporter, and no drugs are recorded to interact with it directly[2][8].
- Other names
- LINC01260RP11-445H22.4
02
Biological functions
Regulation of gene expressionModulation of cell proliferationRegulation of cell migration and invasionApoptosis controlEpithelial-mesenchymal transition (EMT)
03
Disease associations
Cancer - Pancreatic cancerCancer - Lung cancer
04
Biomarkers
Prognostic marker for pancreatic cancerPrognostic marker for lung cancer
Beyond the preview
Go deeper on KCNK15 and WISP2 antisense RNA 1 (KCNK15-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KCNK15 and WISP2 antisense RNA 1 (KCNK15-AS1).